"Rich McKeown brings a deep understanding of the healthcare industry as
the chief executive of one of the nation's most respected healthcare
consulting firms," said ProLung President and CEO Steven Eror when he
announced Leavitt Partners CEO Rich McKeown as the newest member of the
Company's board of directors.
"As Chief of Staff to US Department of Health and Human Services
Secretary Mike Leavitt during the George W. Bush Administration, Mr.
McKeown oversaw the daily operations of the Secretary, which included
managing 27 federal agencies and overseeing the largest federal
departmental budget. His insights and expertise will be valuable as we
enter into an exciting phase of our Company's growth and development
with the launch of distribution and sales in Europe and our continued
efforts to obtain the approvals required to market in the US."
ProLung developed a patented, highly innovative, non-invasive,
non-radiating Electro Pulmonary Nodule Scan, or EPN Scan, as an aid in
the diagnosis of lung cancer, the deadliest form of cancer. In Europe,
the EPN Scan is marketed as Freshmedx. In the US, the Company plans to
market the EPN Scan, subject to FDA approval, as ProLung.
In well-controlled clinical testing published in the Journal
of Thoracic Oncology in 2012, the EPN Scan correctly categorized
patients with malignant lung lesions with a 90% accuracy rate.
"At Leavitt Partners, we collaborate with clients and through our Health
Intelligence Partners forum provide a window into the future of
healthcare," said McKeown. "The ProLung EPN device and Scan is the type
of pioneering medical technology that we need available in the market to
About ProLung: Known as ProLung in the US and Freshmedx in
Europe, the Salt Lake City-based medical technology company is dedicated
to lung health and improving outcomes for lung cancer patients. Its
management has a collective 40 years of relevant healthcare and
biotechnology experience and its researchers feature highly respected
global leaders in lung cancer detection. The technology described in
this release is currently investigational in the US and neither the EPN
Scan nor related statements have been approved by the US FDA. For more
information, please go to www.prolungdx.com
in the US or www.freshmedx.com
This release may contain forward-looking statements as well as
historical information. Forward-looking statements, which are included
in accordance with the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, may involve risks,
uncertainties and other factors that may cause the Company's actual
results and performance in future periods to be materially different
from any future results or performance suggested by the forward-looking
statements in this release. These risks and uncertainties include,
without limitation, the risks that the Company's EPN Scan will not
receive required marketing approval from the FDA for marketing in the
United States and that, even if such approval is received, the EPN Scan
will not prove reliable in identifying likely cancerous masses in
practice to the same extent as in laboratory tests. In addition, other
risks are identified in the company's most recent Annual Report on Form
10-K and Quarterly Report on Form 10-Q filed with the SEC. Such
forward-looking statements speak only as of the date of this release.
The Company expressly disclaims any obligation to update or revise any
forward-looking statements found herein to reflect any changes in
company expectations or results or any change in events.
[ Back To NFVZone's Homepage ]